Next Article in Journal
Time and Mode of Epidemic HCV-2 Subtypes Spreading in Europe: Phylodynamics in Italy and Albania
Next Article in Special Issue
Intradermal Testing Doubles Identification of Allergy among 110 Immunotherapy-Responsive Patients with Eustachian Tube Dysfunction
Previous Article in Journal
Pulmonary Histoplasmosis Mimicking Metastatic Lung Cancer: A Case Report
Previous Article in Special Issue
The Emerging Role of Small Extracellular Vesicles in Inflammatory Airway Diseases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 11
Issue 2
10.3390/diagnostics11020329
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Analyses of the Relation between BPPV and Thyroid Diseases: A Nested Case-Control Study

by
Hyo Geun Choi
1,2,
Young Shin Song
3,
Jee Hye Wee
1,
Chanyang Min
2,4,
Dae Myoung Yoo
4 and
So Young Kim
5,*
1
Department of Otorhinolaryngology-Head & Neck Surgery, Hallym University College of Medicine, Anyang 14068, Korea
2
Hallym Data Science Laboratory, Hallym University College of Medicine, Anyang 14068, Korea
3
Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea
4
Graduate School of Public Health, Seoul National University, Seoul 08826, Korea
5
Department of Otorhinolaryngology-Head & Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea
*
Author to whom correspondence should be addressed.
Diagnostics 2021, 11(2), 329; https://doi.org/10.3390/diagnostics11020329
Submission received: 12 January 2021 / Revised: 28 January 2021 / Accepted: 16 February 2021 / Published: 17 February 2021
(This article belongs to the Special Issue Diagnosis, Management, and Advances in Research on ENT Diseases)
Browse Figures
Versions Notes

Abstract

:
Background: This study investigated relationship between multiple thyroid disorders and benign paroxysmal positional vertigo (BPPV), adjusting for levothyroxine medication. Methods: The Korean National Health Insurance Service-Health Screening Cohort data from 2002 to 2015 were used. A total of 19,071 patients with BPPV were matched with 76,284 participants of a control group in a ratio of 1:4 for age, sex, income, and region of residence. The previous histories of thyroid disorders such as goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis were investigated in both the BPPV and control groups. The odds ratios (ORs) for BPPV in thyroid diseases were calculated using conditional logistic regression analyses. Results: The histories of goiter (5.5% vs. 4.1%), hypothyroidism (4.7% vs. 3.7%), thyroiditis (2.1% vs. 1.6%), and hyperthyroidism (3.1% vs. 2.5%) were higher in the BPPV group than in the control group (all p < 0.001). Goiter, hypothyroidism, thyroiditis, and hyperthyroidism were associated with BPPV (adjusted OR = 1.28 (95% CI = 1.17–1.39) for goiter, 1.23 (95% CI = 1.10–1.37) for hypothyroidism, 1.13 (95% CI = 1.02–1.26) for hyperthyroidism, each p < 0.05). Conclusions: BPPV was associated with thyroid disorders such as goiter, hypothyroidism, thyroiditis, and hyperthyroidism.

1. Introduction

The thyroid hormone plays pivotal roles in physical development, neural differentiation, and metabolic regulation [1]. Hypothyroidism is defined as a reduced thyroxine production or secretion from the thyroid gland. The prevalence rate of hypothyroidism is approximately 1–3% in Western general populations [2,3]. In addition to iodine deficiency, autoimmune thyroiditis is known to cause primary hypothyroidism [3]. Increase or a decrease of thyroid hormones induced by autoimmune stimulation was suggested to cause autoimmune thyroid diseases [4]. Hyperthyroidism, a condition with abnormally high levels of thyroxine, could also be caused by thyroid autoantibodies [5]. In iodine-sufficient areas, the overall prevalence of overt hyperthyroidism was estimated to be approximately 0.2% to 1.3%, and approximately 70–80% of hyperthyroidism was Graves’ disease [5,6]. Thyroid dysfunction of hypothyroidism and/or hyperthyroidism has been reported to be associated with other metabolic diseases like diabetes and dyslipidemia, cardiovascular disease, and audiovestibular disorders [7,8,9,10]. A few previous studies have reported the association of vestibular disorders of Ménière disease and benign paroxysmal positional vertigo (BPPV) with thyroid disorders [11,12].
BPPV is one of the most prevalent vestibular disorders, which is estimated to be approximately 10% of the lifetime incidence in the general population [13]. BPPV is characterized by positional vertigo, which is presumed to be caused by dislodged otoconial debris (canalolithiasis) or otoconia attached to the cupula (cupulolithiasis) in the semicircular canals [14,15]. Although a few related conditions, including immobility, head trauma, and inner ear disease the pathophysiologic cause of BPPV remains elusive [16,17,18]. A few previous researchers presumed that hypothyroidism or autoimmune thyroiditis could induce BPPV via diffusion and gravitational stimulation of the thyroid autoantibody-mediated immune complex in the vestibular labyrinth or co-existing microangiitis as autoimmune multi-organ diseases [19,20]. On the other hand, a case-control study showed no significant association of thyroid-stimulating hormone (TSH) and thyroid autoantibody levels with BPPV [21]. The small study population and potential confounders of levothyroxine medication and lifestyle factors could influence the controversial results. Moreover, besides the potential effects of autoimmunity, metabolic disorders in patients with thyroid disorders have been proposed to be related to vertigo and vestibular disorders [22,23]. Thus, various thyroid disorders could have an impact on BPPV. Only a few previous studies reported the association of BPPV with hyperthyroidism and Hashimoto’s thyroiditis [24,25].
We hypothesized that thyroid disorders, including autoimmune thyroiditis and hyperthyroidism, could affect the occurrence of BPPV. To test this hypothesis, the previous histories of thyroid disorders, including goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis, were analyzed in the BPPV patients compared to control participants adjusting for levothyroxine medication history.

2. Materials and Methods

2.1. Ethical Considerations

This study was approved by the Ethics Committee of Hallym University (2019-10-023, approval date: 5 November 2019). Written informed consent was waived by the Institutional Review Board. All analyses adhered to the guidelines and regulations of the Ethics Committee of Hallym University. A detailed description of the Korean National Health Insurance Service-Health Screening Cohort data has been described elsewhere [26].

2.2. Definition of Benign Paroxysmal Vertigo (Dependent Variable)

Benign paroxysmal vertigo (BPPV) was defined as the diagnosis of ICD-10 codes H811 (Benign paroxysmal vertigo) [27]. We only included participants who were treated ≥2 times by a neurologist or otolaryngologist.

2.3. Definition of Thyroid Diseases and Levothyroxine Use (Independent Variable)

The histories of thyroid diseases and levothyroxine use were collected as our previous study [28]. In brief, goiter (E04: Other nontoxic goiters), hypothyroidism (E02 (subclinical iodine-deficiency hypothyroidism) and E03 (other hypothyroidism)), thyroiditis (E06: Thyroiditis), hyperthyroidism (E05: hyperthyroidism), and autoimmune thyroiditis (E063: autoimmune thyroiditis) were defined based on ICD-10 codes and treatment histories 2 or more times. The prescription histories of levothyroxine for ≥3 months were included as a levothyroxine user.

2.4. Participant Selection

BPPV patients were selected from 514,866 participants with 615,488,428 medical claim codes from 2002 through 2015 (n = 20,866). The control group was included if participants were not defined as BPPV from 2002 through 2015 (n = 494,000). To select the BPPV patient who was diagnosed for the first time, BPPV patients diagnosed in 2002 were excluded (washout periods, n = 716). Control participants were excluded if they had previously been diagnosed with BPPV (n = 25,927). Participants with a history of treated head trauma (ICD-10 codes: S00 to S09, diagnosed by neurologists, neurosurgeons, or emergency medical doctors) or who underwent head and neck CT evaluations (Claim codes: HA401-HA416, HA441-HA443, HA451-HA453, HA461-HA463, or HA471-HA473) were excluded (n = 686 for BPPV, n = 11,913 for control). Participants who were treated for labyrinthitis (ICD-10 codes: H811) ≥2 times (n = 284 for BPPV, n = 972 for control), labyrinthine dysfunction (ICD-10 codes: H832) ≥2 times (n = 69 for BPPV, n = 240 for control), disorder of the acoustic nerve (ICD-10 codes: H933) ≥2 times (n = 18 for BPPV, n = 121 for control), and brain tumor (ICD-10 codes: C70 to C72) ≥2 times (n = 22 for BPPV, n = 797 for control) were excluded. BPPV patients were 1:4 matched with control participants for age, sex, income, and region of residence. To minimize selection bias, the control participants were selected with a random number order. The index date of each BPPV patient was set as the time of BPPV treatment. The index date of the control participants was set as the index date of the matched BPPV patients. Therefore, each BPPV patient matched with control participants had the same index date. During the matching procedure, 377,746 control participants were excluded. Ultimately, 19,071 BPPV patients were 1:4 matched with 76,284 control participants (Figure 1).

2.5. Covariates

The age (10 age groups with 5-year intervals), income (5 classes), and region of residence (urban and rural areas) were grouped as our previous study [29]. Tobacco smoking (nonsmoker, past smoker, and current smoker) and alcohol consumption (<1 time a week and ≥1 time a week) status were categorized. Based on the body mass index (BMI, kg/m2), underweight (BMI < 18.5), normal (18.5 ≤ BMI < 23), overweight (23 ≤ BMI < 25), obese I (25 ≤ BMI < 30), and obese II (BMI ≥ 30) groups were classified [30]. Missing BMI (47/95,355 (0.049%)) was substituted by the average of the final study groups.
The Charlson Comorbidity Index (CCI) excluding cancer and metastatic cancer was calculated as a continuous variable (0 (no comorbidities) through 29 (multiple comorbidities)) [31,32]. Osteoporosis (M80 to M82) was assigned based on the ICD-10 codes, ≥2 times of treatment histories, and the presence of bone density test using X-ray or CT (Claim code: E7001-E7004, HC341-HC345).

2.6. Statistical Analyses

The general characteristics between the BPPV and control groups were compared using the Chi-square test.
To analyze the odds ratios (ORs) with 95% confidence intervals (CIs), a conditional logistic regression model for BPPV in thyroid diseases was calculated. The crude, model 1 (adjusted for obesity, smoking, alcohol consumption, thyroid cancer, osteoporosis, disorders of vestibular function except for BPPV, and CCI scores), and model 2 (additionally adjusted for levothyroxine, goiter, hypothyroidism, thyroiditis, and hyperthyroidism in model 1) were calculated. The analyses were stratified by age, sex, income, and region of residence.
For the subgroup analyses, we divided participants by age and sex (<65 years old and ≥65 years old; men and women) and by income and region of residence (low and high; urban and rural) using crude, model 1, and model 2.
Two-tailed analyses were performed, and significance was defined as p values less than 0.05. SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) was used for statistical analyses.

3. Results

The rates of thyroid diseases such as thyroid cancer, goiter, hypothyroidism, thyroiditis, and hyperthyroidism were higher in the BPPV group than in the control group, except for autoimmune thyroiditis (Table 1). The rate of levothyroxine medication history was higher in the BPPV group than in the control group. The rate of autoimmune thyroiditis was not different between the BPPV and control groups. Age, sex, income, and region of residence were exactly matched between the BPPV and control groups (p = 1.000). The distributions of obesity, smoking status, alcohol consumption, and CCI score were different between the BPPV and control groups (all p < 0.001).
The odds for BPPV increased in patients with a history of thyroid diseases, except for autoimmune thyroiditis (Table 2). The OR of BPPV was 1.13 for the history of levothyroxine medication (95% CI = 1.10–1.30). The OR of BPPV was 1.37 for the history of goiter (95% CI = 1.27–1.47). The OR of BPPV was 1.30 for the history of hypothyroidism (95% CI = 1.20–1.40). The OR of BPPV was 1.30 for the history of thyroiditis (95% CI = 1.16–1.46). The OR of BPPV was 1.26 for the history of hyperthyroidism (95% CI = 1.14–1.38). Because thyroid diseases were correlated with each other (Table S1), they were additionally adjusted (model 2). The increased ORs were not changed for the history of goiter, hypothyroidism, thyroiditis, and hyperthyroidism (adjusted OR = 1.28, 95% CI =1.17–1.39 for goiter, adjusted OR = 1.23, 95% CI =1.10–1.37 for hypothyroidism, and adjusted OR = 1.13, 95% CI = 1.02–1.26 for hyperthyroidism). The history of levothyroxine medication was negatively correlated with BPPV after adjusting for other thyroid diseases (adjusted OR = 0.85, 95% CI = 0.75–0.96).
The associations of thyroid diseases with BPPV differed according to age and sex (Figure 2 and Table S2). The history of goiter was positively associated with BPPV in the <65 years old men subgroup. In the ≥65 years old men subgroup, the history of hypothyroidism was positively related with BPPV. In the <65 years old women subgroup, goiter, hypothyroidism, and hyperthyroidism were positively related with BPPV. In the ≥65 years old women subgroup, the history of hypothyroidism was positively associated with BPPV.
According to the income and region of residence, the history of goiter was positively related with BPPV in all subgroups except for high income, rural subgroup (Figure 3 and Table S3). The history of hypothyroidism was positively associated with BPPV in the low income, urban subgroup, and high income, rural subgroup. The history of thyroiditis was positively associated with BPPV in the high income, rural subgroup.

4. Discussion

Thyroid diseases such as goiter, hypothyroidism, thyroiditis, and hyperthyroidism were related to BPPV in the present study. Both hyper- and hypothyroidism were associated with BPPV. On the other hand, autoimmune thyroiditis did not reveal a statistically significant association with BPPV. According to age and sex, the young women (<65 years old) subgroup showed a higher number of thyroid diseases (goiter, hypothyroidism, and hyperthyroidism) related to BPPV. Although a few prior studies suggested the association of autoimmune thyroiditis with BPPV [20,33] to the best of our knowledge, only a few previous studies have investigated the association of other thyroid diseases with BPPV.
A few previous studies have indicated a relationship between thyroid disease and BPPV [20,33,34]. A case-control study reported a higher rate of hypothyroidism and autoimmune chronic thyroiditis in the BPPV group than in the control group (21% (28/134) vs. 0.02% (2/100) for hypothyroidism and 34% (46/134) vs. 0.02% (2/100) for autoimmune chronic thyroiditis, both p < 0.001) [20]. A cross-sectional study demonstrated a higher recurrence rate of BPPV in patients taking thyroid hormone medication (OR = 1.90, p = 0.001) [34]. However, in the present study, the history of levothyroxine medication did not show a positive association with BPPV. This could imply that, there is less importance of the status of thyroid function for the risk of BPPV. To support this, a prospective study demonstrated a high rate of BPPV in patients with Hashimoto’s thyroiditis and euthyroid state, compared to healthy control participants (18% (36/ 200) vs. 2% (2/ 200)) [19]. They proposed that thyroid autoantibodies might be crucial for the risk of BPPV [19]. Our previous study demonstrated the association of another cochleovestibular disease, Meniere’s disease, with thyroid diseases of goiter, hypothyroidism, and hyperthyroidism [28]. Thus, the impacts of thyroid diseases on vestibular system could be inferred. Autoimmune dysfunction, dysregulation of endolymphatic flow, and insufficient blood flow of inner ear could mediate the association of thyroid diseases with vestibular dysfunction.
In the present study, autoimmune thyroiditis did not show a significant difference between the BPPV and control groups. The relatively small number of patients with autoimmune thyroiditis could attenuate statistical power. In model 2, autoimmune thyroiditis was not adjusted because it was included in thyroiditis. Although autoimmune thyroiditis was not related to BPPV, thyroiditis was associated with BPPV in this study. Thus, the possible impact of the autoimmune mechanism on BPPV could not be excluded from these present results. Hyperthyroidism and hypothyroidism were positively related with BPPV in this study. Thyroid diseases have common pathophysiology with that of autoimmune response in Graves’ disease and Hashimoto thyroiditis, with genetic or epigenetic susceptibilities [35]. Moreover, levothyroxine medication in patients with hypothyroidism could induce hypothyroidism. For instance, approximately 9.6% of hypothyroidism was attributed to the medication for a previous hyperthyroidism [36]. We analyzed for model 2 to consider the contributions of each thyroid disease on BPPV, in addition to model 1, which analyzed the association of each thyroid disease with BPPV, respectively.
Thyroid autoantibodies could induce autoimmune-complex precipitations in the inner ear, which might change the endolymphatic flow and provoke BPPV. The diffusion of immune-complex of autoimmune thyroiditis patients in the vestibular labyrinth was suggested to increase the risk of BPPV [33]. In addition, the thyroid autoantibody immune complexes in the vestibular system could stimulate the vestibular receptors that evoke vertigo as BPPV [19]. Moreover, autoimmune diseases can manifest in multiple organs of the vestibular labyrinth [33]. Likewise, in the case of thyroid autoantibodies, a case series described the risk of positional vertigo in patients with macroglobulinemia, probably due to the diffusion of macroglobulins in the inner ear [37]. In addition, the association of the autoimmune disease with Vertigo has been suggested [38].
Changes in the endolymphatic ionic composition of the vestibular labyrinth could mediate the BPPV in patients with abnormal thyroid function. It has been suggested that the volume or compositional changes of the endolymph of the vestibular labyrinth could induce BPPV [33,39]. For instance, patients with Pendred syndrome, which is caused by defects in anion exchanger pendrin, often have enlarged vestibular aqueduct (EVA) with recurrent vertigo and hypothyroidism with goiter due to abnormal iodine organification [40,41]. Patients with EVA are known to be prone to BPPV, probably due to the volume or compositional change of the endolymph of the vestibular labyrinth [39,42]. The expression of ion transporters, including sodium iodide symporter and pendrin, could be changed according to thyroid function, which might influence the composition of the endolymph [43,44]. The transcript expression levels of pendrin were reported to be up- and down-regulated in patients with Graves’ disease and Hashimoto thyroiditis, respectively [43]. Therefore, changes in endolymphatic composition could promote the absorption or precipitation of otoconial debris and induce BPPV in patients with abnormal thyroid function.
The impaired microcirculation of blood flow in the inner ear could be linked to the higher rate of BPPV in patients with thyroid disease. It has been reported that the ischemia of the vestibular labyrinth might be one of the predisposing factors for BPPV [45,46]. A case-control study described that the high stimulus rate brainstem auditory evoked potential wave latencies; which is one of the markers for ischemia of the labyrinth, was delayed in BPPV patients compared to those of controls [45]. A prospective study reported that the risk of BPPV was increased in patients with giant cell arteritis compared to controls, probably due to ischemic complications [46]. Moreover, a few clinical studies, including randomized controlled trials [47,48], reported the therapeutic effects of the improvement of blood flow in the inner ear using betahistine in BPPV patients [49]. Several previous studies have suggested an association between abnormal levels of thyroid-related hormones and cardiovascular circulations [50,51]. Some prior studies have proposed increased thyroid-related hormones, including T3 and T4, in conditions of acute systemic ischemia [50]. On the other hand, reduced levels of thyroid-related hormones were also related to cardiovascular compromise [9,51]. Abnormal thyroid function is thought to induce dyslipidemia, endothelial dysfunction, changes in blood pressure, and myocardial dysfunction which elevates the risk of cardiovascular disease and systemic ischemia [9]. Therefore, abnormal thyroid-related hormone levels could reduce blood flow in the inner ear and the risk of BPPV.
This study delineated the association of multiple thyroid disorders, including goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis, with the incidence of BPPV. Few previous studies have comprehensively investigated the relationship between multiple thyroid diseases and BPPV. Using the large, representative cohort population, the present study demonstrated the positive relationship of each thyroid disease with BPPV. In addition, many comorbidities, lifestyle factors of obesity, smoking, alcohol consumption, and levothyroxine medication were adjusted to attenuate the potential confounding effects. However, this study could not assess the thyroid function and autoimmune antibody status of each participant. Thyroid cancer could not be differentiated according to subtypes. Because microcarcinoma could be diagnosed in Korea by national screening program, the incidence of thyroid cancer may have ethnic differences. However, the proportion of thyroid cancer was small in our cohort, in that the impact of subtypes of thyroid cancer on the association between thyroid diseases and BPPV may not be high. There may have the ethnic difference on the association between thyroid diseases and BPPV, due to the differences on the prevalence of thyroid diseases according to the ethnicity and iodine nutrition [6]. Further, because this study was based on health claims data, patients who did not visit the clinic could be missed. For the diagnosis of BPPV, the types of BPPV could not be differentiated. Future studies are needed to unravel the specific causality between thyroid diseases and the types of BPPV.

5. Conclusions

Both hyperthyroidism and hypothyroidism, in addition to autoimmune thyroiditis, were associated with an increased rate of BPPV. The relationship between hypothyroidism and BPPV was consistent according to age, sex, income, or region of residence.

Supplementary Materials

The following are available online at https://www.mdpi.com/2075-4418/11/2/329/s1, Table S1. Pearson’s chi-square test between each of levothyroxine, goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis; Table S2. Subgroup analyses of crude and adjusted odd ratios (95% confidence interval) for BPPV in levothyroxine, goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis according to age and sex; Table S3 Subgroup analyses of crude and adjusted odd ratios (95% confidence interval) for BPPV in levothyroxine, goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis according to income and region.

Author Contributions

Conceptualization, H.G.C. and S.Y.K.; methodology, H.G.C.; formal analysis, C.M. and D.M.Y.; writing—original draft preparation, H.G.C., Y.S.S., J.H.W. and S.Y.K.; writing—review and editing, H.G.C., Y.S.S., J.H.W. and S.Y.K.; funding acquisition, H.G.C. and S.Y.K. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported in part by a research grant (NRF-2018-R1D1A1A02085328 and 2020R1A2C4002594) from the National Research Foundation (NRF) of Korea. The APC was funded by 2020R1A2C4002594.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Hallym University (2019–10–023, approval date: 5 November 2019).

Informed Consent Statement

Patient consent was waived by the Institutional Review Board of Hallym University.

Data Availability Statement

Releasing of the data by the researcher is not allowed legally. All of data are available from the database of National health Insurance Sharing Service (NHISS) (https://nhiss.nhis.or.kr/ (accessed on 17 February 2021)). NHISS allows all of this data for the any researcher who promises to follow the research ethics with some cost. If you want to access the data of this article, you could download it from the website after promising to follow the research ethics.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Brent, G.A. Mechanisms of thyroid hormone action. J. Clin. Investig. 2012, 122, 3035–3043. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Giorda, C.B.; Carna, P.; Romeo, F.; Costa, G.; Tartaglino, B.; Gnavi, R. Prevalence, incidence and associated comorbidities of treated hypothyroidism: An update from a European population. Eur. J. Endocrinol. 2017, 176, 533–542. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Vanderpump, M.P.; Tunbridge, W.M. Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid 2002, 12, 839–847. [Google Scholar] [CrossRef]
  4. Trovato, M. A historical excursus of diagnostic methods for Hashimoto thyroiditis and Graves’ disease. Gazz. Med. Ital. Arch. Sci. Med. 2020, 179, 479–485. [Google Scholar] [CrossRef]
  5. Nyström, H.F.; Jansson, S.; Berg, G.E.B. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003–2005. Clin. Endocrinol. 2013, 78, 768–776. [Google Scholar] [CrossRef]
  6. Taylor, P.N.; Albrecht, D.; Scholz, A.; Gutierrez-Buey, G.; Lazarus, J.H.; Dayan, C.M.; Okosieme, O.E. Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol. 2018, 14, 301–316. [Google Scholar] [CrossRef]
  7. Biondi, B.; Kahaly, G.J.; Robertson, R.P. Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders. Endocr. Rev. 2019, 40, 789–824. [Google Scholar] [CrossRef] [Green Version]
  8. Wolffenbuttel, B.H.R.; Wouters, H.J.C.M.; Slagter, S.N.; Van Waateringe, R.P.; Kobold, A.C.M.; Van Vliet-Ostaptchouk, J.V.; Links, T.P.; Van Der Klauw, M.M. Thyroid function and metabolic syndrome in the population-based LifeLines cohort study. BMC Endocr. Disord. 2017, 17, 65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Jabbar, A.; Pingitore, A.; Pearce, S.H.S.; Zaman, A.J.A.; Iervasi, A.P.G.; Razvi, A.J.S.H.S.P.A.Z.S. Thyroid hormones and cardiovascular disease. Nat. Rev. Cardiol. 2017, 14, 39–55. [Google Scholar] [CrossRef]
  10. Andrade, C.L.O.; Machado, G.C.; Fernandes, L.D.C.; Albuquerque, J.M.; Casais-E-Silva, L.L.; Ramos, H.E.; Alves, C.A.D. Mechanisms involved in hearing disorders of thyroid ontogeny: A literature review. Arch. Endocrinol. Metab. 2017, 61, 501–505. [Google Scholar] [CrossRef] [Green Version]
  11. Chiarella, G.G.; Russo, D.; Monzani, F.F.; Petrolo, C.C.; Fattori, B.B.; Pasqualetti, G.; Cassandro, E.E.; Costante, G. Hashimoto Thyroiditis and Vestibular Dysfunction. Endocr. Pract. 2017, 23, 863–868. [Google Scholar] [CrossRef]
  12. Chiarella, G.; Tognini, S.; Nacci, A.; Sieli, R.; Costante, G.; Petrolo, C.; Mancini, V.; Guzzi, P.H.; Pasqualetti, G.; Cassandro, E.; et al. Vestibular disorders in euthyroid patients with Hashimoto’s thyroiditis: Role of thyroid autoimmunity. Clin. Endocrinol. 2014, 81, 600–605. [Google Scholar] [CrossRef]
  13. Von Brevern, M.; Radtke, A.; Lezius, F.; Feldmann, M.; Ziese, T.; Lempert, T.; Neuhauser, H. Epidemiology of benign paroxysmal positional vertigo: A population based study. J. Neurol. Neurosurg. Psychiatry 2007, 78, 710–715. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Von Brevern, M.; Bertholon, P.; Brandt, T.; Fife, T.; Imai, T.; Nuti, D.; Newman-Toker, D. Benign paroxysmal positional vertigo: Diagnostic criteria. J. Vestib. Res. 2015, 25, 105–117. [Google Scholar] [CrossRef] [Green Version]
  15. Brandt, T.; Steddin, S. Current view of the mechanism of benign paroxysmal positioning vertigo: Cupulolithiasis or canalolithiasis? J. Vestib. Res. 1993, 3, 373–382. [Google Scholar]
  16. Luryi, A.L.; Lawrence, J.; Larouere, M.; Babu, S.; Bojrab, D.I.; Zappia, J.; Sargent, E.W.; Schutt, C.A. Treatment of Patients with Benign Paroxysmal Positional Vertigo and Severe Immobility Using the Particle Repositioning Chair: A Retrospective Cohort Study. Ann. Otol. Rhinol. Laryngol. 2018, 127, 390–394. [Google Scholar] [CrossRef]
  17. Mumford, C.J. Post-traumatic benign paroxysmal positional vertigo. Pract. Neurol. 2019, 19, 354–355. [Google Scholar] [CrossRef]
  18. Riga, M.; Bibas, A.G.; Xenellis, J.; Korres, S. Inner ear disease and benign paroxysmal positional vertigo: A critical review of incidence, clinical characteristics, and management. Int. J. Otolaryngol. 2011, 2011, 1–7. [Google Scholar] [CrossRef] [Green Version]
  19. Papi, G.; Guidetti, G.; Corsello, S.M.; Di Donato, C.; Pontecorvi, A. The association between benign paroxysmal positional vertigo and autoimmune chronic thyroiditis is not related to thyroid status. Thyroid 2010, 20, 237–238. [Google Scholar] [CrossRef]
  20. Papi, G.; Corsello, S.M.; Milite, M.T.; Zanni, M.; Ciardullo, A.V.; Donato, C.D.; Pontecorvi, A. Association between benign paroxysmal positional vertigo and autoimmune chronic thyroiditis. Clin. Endocrinol. 2009, 70, 169–170. [Google Scholar] [CrossRef] [PubMed]
  21. Sari, K.; Yildirim, T.; Börekçi, H.; Akin, I.; Aydin, R.; Ozkiris, M. The relationship between benign paroxysmal positional vertigo and thyroid autoimmunity. Acta Otolaryngol. 2015, 135, 754–757. [Google Scholar] [CrossRef]
  22. Santos, M.D.; Bittar, R.S.M. Vertigo and metabolic disorders. Int. Tinnitus J. 2012, 17, 16–20. [Google Scholar]
  23. Rybak, L.P. Metabolic disorders of the vestibular system. Otolaryngol. Head Neck Surg. 1995, 112, 128–132. [Google Scholar] [CrossRef]
  24. Hsu, C.L.; Tsai, S.J.; Shen, C.C.; Lu, T.; Hung, Y.M.; Hu, L.Y. Risk of benign paroxysmal positional vertigo in patients with depressive disorders: A nationwide population-based cohort study. BMJ Open 2019, 9, e026936. [Google Scholar] [CrossRef] [Green Version]
  25. Miskiewicz-Orczyk, K.A.; Lisowska, G.; Kajdaniuk, D.; Wojtulek, M. Can Hashimoto’s thyroiditis cause vertigo? [Czy choroba Hashimoto moze byc przyczyna zawrotow glowy?]. Endokrynol. Pol. 2020, 70, 76–86. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Kim, S.Y.; Min, C.; Oh, D.J.; Choi, H.G. Tobacco Smoking and Alcohol Consumption Are Related to Benign Parotid Tumor: A Nested Case-Control Study Using a National Health Screening Cohort. Clin. Exp. Otorhinolaryngol. 2019, 12, 412–419. [Google Scholar] [CrossRef] [Green Version]
  27. Choi, H.G.; Lee, J.K.; Kong, I.G.; Lim, H.; Kim, S.Y. Osteoporosis increases the risk of benign paroxysmal positional vertigo: A nested case-control study using a national sample cohort. Eur. Arch. Oto Rhino Laryngol. 2019, 276, 335–342. [Google Scholar] [CrossRef] [PubMed]
  28. Kim, S.Y.; Song, Y.S.; Wee, J.H.; Min, C.; Yoo, D.M.; Choi, H.G. Association between Meniere’s disease and thyroid diseases: A nested case-control study. Sci. Rep. 2020, 10, 18224. [Google Scholar] [CrossRef]
  29. Kim, S.Y.; Min, C.; Oh, D.J.; Choi, H.G. Bidirectional Association Between GERD and Asthma: Two Longitudinal Follow-Up Studies Using a National Sample Cohort. J. Allergy Clin. Immunol. Pract. 2020, 8, 1005–1013.e9. [Google Scholar] [CrossRef]
  30. World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific Perespective: Redefining Obesity and its Treatment; Health Communications Australia: Sydney, Australia, 2000. [Google Scholar]
  31. Quan, H.; Li, B.; Couris, C.M.; Fushimi, K.; Graham, P.; Hider, P.; Januel, J.M.; Sundararajan, V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 2011, 173, 676–682. [Google Scholar] [CrossRef] [Green Version]
  32. Quan, H.; Sundararajan, V.; Halfon, P.; Fong, A.; Burnand, B.; Luthi, J.C.; Saunders, L.D.; Beck, C.A.; Feasby, T.E.; Ghali, W.A. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care 2005, 43, 1130–1139. [Google Scholar] [CrossRef] [PubMed]
  33. Modugno, G.C.; Pirodda, A.; Ferri, G.G.; Montana, T.; Rasciti, L.; Ceroni, A.R. A relationship between autoimmune thyroiditis and benign paroxysmal positional vertigo? Med. Hypotheses 2000, 54, 614–615. [Google Scholar] [CrossRef] [PubMed]
  34. Picciotti, P.M.; Di Cesare, T.; Tricarico, L.; De Corso, E.; Galli, J.; Paludetti, G. Is drug consumption correlated with benign paroxysmal positional vertigo (BPPV) recurrence? Eur. Arch. Oto Rhino Laryngol. 2020, 277, 1609–1616. [Google Scholar] [CrossRef]
  35. Tomer, Y. Mechanisms of autoimmune thyroid diseases: From genetics to epigenetics. Annu. Rev. Pathol. 2014, 9, 147–156. [Google Scholar] [CrossRef] [Green Version]
  36. Diez, J.J. Hypothyroidism in patients older than 55 years: An analysis of the etiology and assessment of the effectiveness of therapy. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57, M315–M320. [Google Scholar] [CrossRef] [Green Version]
  37. Keim, R.J.; Sachs, G.B. Positional nystagmus in association with macroglobulinemia. Ann. Otol. Rhinol. Laryngol. 1975, 84, 223–227. [Google Scholar] [CrossRef]
  38. Girasoli, L.; Cazzador, D.; Padoan, R.; Nardello, E.; Felicetti, M.; Zanoletti, E.; Schiavon, F.; Bovo, R. Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment. J. Immunol. Res. 2018, 2018, 1–16. [Google Scholar] [CrossRef]
  39. Manzari, L. Enlarged vestibular aqueduct (EVA) related with recurrent benign paroxysmal positional vertigo (BPPV). Med. Hypotheses 2008, 70, 61–65. [Google Scholar] [CrossRef]
  40. Wemeau, J.L.; Kopp, P. Pendred syndrome. Best Pract. Res. Clin. Endocrinol. Metab. 2017, 31, 213–224. [Google Scholar] [CrossRef]
  41. Sugiura, M.; Sato, E.; Nakashima, T.; Sugiura, J.; Furuhashi, A.; Yoshino, T.; Nakayama, A.; Mori, N.; Murakami, H.; Naganawa, S. Long-term follow-up in patients with Pendred syndrome: Vestibular, auditory and other phenotypes. Eur. Arch. Oto Rhino Laryngol. 2005, 262, 737–743. [Google Scholar] [CrossRef]
  42. Song, J.-J.; Hong, S.K.; Kim, J.S.; Koo, J.-W. Enlarged vestibular aqueduct may precipitate benign paroxysmal positional vertigo in children. Acta Otolaryngol. 2012, 132, S109–S117. [Google Scholar] [CrossRef] [PubMed]
  43. Belguith-Maalej, S.; Rebuffat, S.A.; Charfeddine, I.; Mnif, M.; Nadir, R.F.; Abid, M.; Ghorbel, A.; Peraldi-Roux, S.; Ayadi, H.; Hadj-Kacem, H. SLC26A4 expression among autoimmune thyroid tissues. Immunobiology 2011, 216, 571–578. [Google Scholar] [CrossRef]
  44. Mian, C.; Lacroix, L.; Alzieu, L.; Nocera, M.; Talbot, M.; Bidart, J.M.; Schlumberger, M.; Caillou, B. Sodium iodide symporter and pendrin expression in human thyroid tissues. Thyroid 2001, 11, 825–830. [Google Scholar] [CrossRef]
  45. He, J.W.; Gong, Q.; Wang, X.F.; Xiao, Z. High stimulus rate brainstem auditory evoked potential in benign paroxysmal positional vertigo. Eur. Arch. Oto Rhino Laryngol. 2015, 272, 2095–2100. [Google Scholar] [CrossRef] [PubMed]
  46. Amor-Dorado, J.C.; Llorca, J.; Costa-Ribas, C.; Garcia-Porrua, C.; Gonzalez-Gay, M.A. Giant cell arteritis: A new association with benign paroxysmal positional vertigo. Laryngoscope 2004, 114, 1420–1425. [Google Scholar] [CrossRef] [PubMed]
  47. Kaur, J.; Shamanna, K. Management of Benign Paroxysmal Positional Vertigo: A Comparative Study between Epleys Manouvre and Betahistine. Int. Tinnitus J. 2017, 21, 30–34. [Google Scholar] [CrossRef] [Green Version]
  48. Jalali, M.M.; Gerami, H.; Saberi, A.; Razaghi, S. The Impact of Betahistine versus Dimenhydrinate in the Resolution of Residual Dizziness in Patients with Benign Paroxysmal Positional Vertigo: A Randomized Clinical Trial. Ann. Otol Rhinol Laryngol. 2020, 129, 434–440. [Google Scholar] [CrossRef] [PubMed]
  49. Murdin, L.; Hussain, K.; Schilder, A.G. Betahistine for symptoms of vertigo. Cochrane Database Syst. Rev. 2016, CD010696. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Tani, N.; Ishikawa, M.; Watanabe, M.; Ikeda, T.; Ishikawa, T. Thyroid-related hormones as potential markers of hypoxia/ischemia. Hum. Cell 2020, 33, 545–558. [Google Scholar] [CrossRef] [Green Version]
  51. Razvi, S. Novel uses of thyroid hormones in cardiovascular conditions. Endocrine 2019, 66, 115–123. [Google Scholar] [CrossRef] [Green Version]
Diagnostics 11 00329 g001 550
Figure 1. A schematic illustration of the participant selection process that was used in the present study.
Figure 1. A schematic illustration of the participant selection process that was used in the present study.
Diagnostics 11 00329 g001
Diagnostics 11 00329 g002 550
Figure 2. The odds ratios (95% confidence interval) of levothyroxine medication, goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis for benign paroxysmal positional vertigo according to age and sex.
Figure 2. The odds ratios (95% confidence interval) of levothyroxine medication, goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis for benign paroxysmal positional vertigo according to age and sex.
Diagnostics 11 00329 g002
Diagnostics 11 00329 g003 550
Figure 3. The odds ratios (95% confidence interval) of levothyroxine medication, goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis for benign paroxysmal positional vertigo according to region of residence.
Figure 3. The odds ratios (95% confidence interval) of levothyroxine medication, goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis for benign paroxysmal positional vertigo according to region of residence.
Diagnostics 11 00329 g003
Table
Table 1. General Characteristics of Participants.
Table 1. General Characteristics of Participants.
CharacteristicsTotal Participants
BPPV (n, %)Control (n, %)p-Value
Age (years old) 1.000
40–44250 (1.3)1000 (1.3)
45–491359 (7.1)5436 (7.1)
50–542939 (15.4)11,756 (15.4)
55–593338 (17.5)13,352 (17.5)
60–643302 (17.3)13,208 (17.3)
65–693083 (16.2)12,332 (16.2)
70–742524 (13.2)10,096 (13.2)
75–791551 (8.1)6204 (8.1)
80–84579 (3.0)2316 (3.0)
85+
Sex 1.000
Male6878 (36.1)27,512 (36.1)
Female12,193 (63.9)48,772 (63.9)
Income 1.000
1 (lowest)2961 (15.5)11,844 (15.5)
22295 (12.0)9180 (12.0)
32875 (15.1)11,500 (15.1)
44081 (21.4)16,324 (21.4)
5 (highest)6859 (36.0)27,436 (36.0)
Region of residence 1.000
Urban8689 (45.6)34,756 (45.6)
Rural10,382 (54.4)41,528 (54.4)
Obesity † <0.001 *
Underweight385 (2.0)1935 (2.5)
Normal6392 (33.5)27,089 (35.5)
Overweight5428 (28.5)20,652 (27.1)
Obese I6263 (32.8)24,098 (31.6)
Obese II603 (3.2)2510 (3.3)
Smoking status <0.001 *
Nonsmoker15,397 (80.7)60,147 (78.9)
Past smoker2003 (10.5)7047 (9.2)
Current smoker1671 (8.8)9090 (11.9)
Alcohol consumption <0.001 *
<1 time a week14,398 (75.5)55,586 (72.9)
≥1 time a week4673 (24.5)20,698 (27.1)
CCI score
012,245 (64.2)52,632 (69.0)<0.001 *
13376 (17.7)10,586 (13.9)
21731 (9.1)6030 (7.9)
3804 (4.2)3040 (4.0)
≥4915 (4.8)3996 (5.2)
Thyroid cancer 367 (1.9)298 (1.7)0.036 *
Osteoporosis6091 (31.9)20,328 (26.7)<0.001 *
Period of taking levothyroxine <0.001 *
<3month18,313 (96.0)73,728 (96.7)
≥3month758 (4.0)2556 (3.4)
Goiter1051 (5.5)3132 (4.1)<0.001 *
Hypothyroidism898 (4.7)2809 (3.7)<0.001 *
Thyroiditis400 (2.1)1241 (1.6)<0.001 *
Hyperthyroidism583 (3.1)1870 (2.5)<0.001 *
Autoimmune thyroiditis142 (0.7)510 (0.7)0.254
Abbreviations: CCI, Charlson comorbidity index; BPPV, Benign Paroxysmal Positional Vertigo * Chi-square test. Significance at p < 0.05. † Obesity (BMI, body mass index, kg/m2) was categorized as <18.5 (underweight), ≥18.5 to <23 (normal), ≥23 to <25 (overweight), ≥25 to <30 (obese I), and ≥30 (obese II).
Table
Table 2. Crude and adjusted odd ratios (95% confidence interval) for BPPV in levothyroxine, goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis.
Table 2. Crude and adjusted odd ratios (95% confidence interval) for BPPV in levothyroxine, goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis.
CharacteristicsOdd Ratios for BPPV
Crude †p-ValueModel 1 †,‡p-ValueModel 2 †,§p-Value
Total participants (n = 95,355)
Levothyroxine1.20 (1.10–1.30)<0.001 *1.13 (1.03–1.24)0.014 *0.85 (0.75–0.96)0.011 *
Goiter1.37 (1.27–1.47)<0.001 *1.31 (1.21–1.42)<0.001 *1.28 (1.17–1.39)<0.001 *
Hypothyroidism1.30 (1.20–1.40)<0.001 *1.24 (1.13–1.35)<0.001 *1.23 (1.10–1.37)<0.001 *
Thyroiditis1.30 (1.16–1.46)<0.001 *1.28 (1.13–1.44)<0.001 *1.16 (1.02–1.32)0.025 *
Hyperthyroidism1.26 (1.14–1.38)<0.001 *1.21 (1.09–1.34)<0.001 *1.13 (1.02–1.26)0.023 *
Autoimmune thyroiditis1.12 (0.93–1.34)0.2541.15 (0.94–1.41)0.169
Abbreviations: CCI, Charlson comorbidity index; BPPV, Benign Paroxysmal Positional Vertigo. * Conditional logistic regression model, Significance at p < 0.05. † Models stratified by age, sex, income, and region of residence. ‡ Model 1 was adjusted for obesity, smoking, alcohol consumption, thyroid cancer, osteoporosis, disorders of vestibular function, and CCI scores. § Model 2 was adjusted for model 1 plus levothyroxine, goiter, hypothyroidism, thyroiditis, hyperthyroidism.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Choi, H.G.; Song, Y.S.; Wee, J.H.; Min, C.; Yoo, D.M.; Kim, S.Y. Analyses of the Relation between BPPV and Thyroid Diseases: A Nested Case-Control Study. Diagnostics 2021, 11, 329. https://doi.org/10.3390/diagnostics11020329

AMA Style

Choi HG, Song YS, Wee JH, Min C, Yoo DM, Kim SY. Analyses of the Relation between BPPV and Thyroid Diseases: A Nested Case-Control Study. Diagnostics. 2021; 11(2):329. https://doi.org/10.3390/diagnostics11020329

Chicago/Turabian Style

Choi, Hyo Geun, Young Shin Song, Jee Hye Wee, Chanyang Min, Dae Myoung Yoo, and So Young Kim. 2021. "Analyses of the Relation between BPPV and Thyroid Diseases: A Nested Case-Control Study" Diagnostics 11, no. 2: 329. https://doi.org/10.3390/diagnostics11020329

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop